Stifel analyst Rick Wise commented on the "60 Minutes" story regarding Boston Scientific transvaginal mesh products and associated lawsuits, calling the report "unsettling...but likely overstated." He notes that the company has reached or is near settlement on 47,500 of the known 49,500 mesh legal claims, has a $1.5B legal reserve for the matter and has said it expects the majority of the remaining mesh claims to be resolved in 2018. Wise keeps a Buy rating and $33 price target on Boston Scientific shares.
After Boston Scientific announced an agreement to acquire BTG for about $4.2B, Piper Jaffray analyst Matt O'Brien said the deal "looks like a headscratcher" at first glance, but he believes it will turn out to be a favorable transaction the more that he thinks about it. There is the clear opportunity to expand BTG's presence internationally and adding more therapeutic products in oncology provides a significant synergistic opportunity, O'Brien tells investors. Boston Scientific has proven capable of "acquiring solid assets and making them even better," said O'Brien, who believes that will be the case again. He maintains an Overweight rating and $40 price target on Boston Scientific shares.